1401063-53-3

Upstream product

• 1401003-59-5 C₁₉H₂₂F₃N₃O₃ 
• 123324-71-0 p-tert-butylphenylboronic acid 
• 1604-44-0 N-α-trifluoroacetyl-L-histidine methyl ester 

Downstream Products

• 1613201-61-8 His(4-t-butylphenyl)-NHBzl 
• 1613201-67-4 Boc-Trp-His(4-t-butylphenyl)-NHBzl 
• 1613201-73-2 Trp-His(4-t-butylphenyl)-NHBzl 
• 1613201-81-2 Boc-Trp-His(4-t-butylphenyl)-OMe 
• 1613201-87-8 Trp-His(4-t-butylphenyl)-OMe 
• 1537176-78-5 Boc-His(4-t-butylphenyl)-Arg-NHBzl 
• 1613201-42-5 His(4-t-butylphenyl)-Arg-NHBzl 
• 1537176-81-0 Boc-His(4-t-butylphenyl)-Arg-OMe 
• 1613201-49-2 His(4-t-butylphenyl)-Arg-OMe 
• 1613201-55-0 N-α-Boc-L-His(4-t-butylphenyl)-NHBzl 
• 1401003-85-7 C₂₁H₂₉N₃O₄ 

Relevant academic research and scientific papers

Synthesis and antimicrobial activities of His(2-aryl)-Arg and Trp-His(2-aryl) classes of dipeptidomimetics

In this communication, we report the design, synthesis and in vitro antimicrobial activity of ultra short peptidomimetics. Besides producing promising antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA), the dipeptidomimetics exhibited high antifungal activity against C. neoformans with IC50 values in the range of 0.16-19 μg mL-1. The most potent analogs exhibited 4-fold higher activity than the currently used drug amphotericin B, with no apparent cytotoxicity in a panel of mammalian cell lines. This journal is the Partner Organisations 2014.